No Data
Express News | Day One Biopharmaceuticals Inc : JP Morgan Raises Target Price to $39 From $36
J.P. Morgan Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating
Day One Biopharmaceuticals: Strong Ojemda Launch Exceeds Expectations, Analyst Reiterates Overweight Rating
Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts
Day One Biopharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
No Data
No Data